Soc. Generale Knock-Out GNMSF/ DE000CL9G895 /
5/30/2024 9:22:51 AM | Chg.-0.24 | Bid8:16:58 PM | Ask8:16:58 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
2.15EUR | -10.04% | 2.36 Bid Size: 1,300 |
2.60 Ask Size: 1,300 |
Genmab A/S | 1,777.2745 - | 12/31/2078 | Call |
GlobeNewswire
4/30
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
4/3
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire
10/17/2023
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire
9/25/2023
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire
9/4/2023
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire
10/19/2021
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
GlobeNewswire
9/20/2021
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previous...
GlobeNewswire
7/21/2021
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021